



ORIGINAL ARTICLE

Adaptation and validation of the ICU Mobility Scale in Spain[☆]



S. Arias-Rivera (RN)^{a,b}, M. Raurell-Torredà (RN, MsC, PhD)^{c,*},
I.J. Thuissard-Vasallo (MsC)^d, C. Andreu-Vázquez (MVD, MRes, PhD)^e,
C.L. Hodgson (PhD, FACP BAppSc (PT))^{f,g}, Grupo IMS-Es¹ Grupo MOviPre²,

^a Hospital Universitario de Getafe, Getafe, Madrid, Spain

^b CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

^c Facultad Medicina y Ciencias de la Salud, Universidad de Barcelona, Barcelona, Spain

^d Escuela de Doctorado e Investigación. Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain

^e Departamento Farmacia y Biotecnología, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain

^f Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia

^g Physiotherapy Department, Alfred Health, Melbourne, Victoria, Australia

Received 22 April 2019; accepted 5 October 2019

KEYWORDS

Critical care;
early mobilization;
muscle weakness;
validation studies;
validity;
reliability;
responsiveness

Abstract

Objective: To adapt the ICU Mobility Scale (IMS) to the area of intensive care units (ICU) in Spain and to evaluate the metric properties of the Spanish version of the IMS (IMS-Es).

Method: Descriptive metric study developed in two phases. Phase 1, adaptation to Spanish of the IMS by a team of nurses and physiotherapists (translation, pilot, backtranslation and agreement). Phase 2, analysis of metric properties (convergent, divergent and predictive validity, interobserver reliability, sensitivity and minimum important difference) of the IMS-Es. Patient characteristics (Barthel, Charlson, BMI, sex), sedation/agitation level (RASS), ICU and hospital stays, survival, quality of life (SF-12), muscle weakness (MRC-SS) and mobility (IMS-Es) were recorded in the patients of the MOviPre national multicentre study.

Results: After obtaining the IMS-Es, it was implemented in 645 patients from 80 Spanish ICUs between April and June 2017. **Convergent validity:** moderate correlation between IMS-Es and MRC-SS ($r = .389$; $p < .001$) and significant comparison between groups with and without ICU-acquired weakness ($p < .001$). **Divergent validity:** no correlation between

DOI of original article: <https://doi.org/10.1016/j.enfi.2019.10.001>

[☆] Please cite this article as: Arias-Rivera S, Raurell-Torredà M, Thuissard-Vasallo IJ, Andreu-Vázquez C, Hodgson CL. Adaptación y validación de la *UCI Mobility Scale* en España. *Enferm Intensiva*. 2020;31:131–146.

* Corresponding author.

E-mail addresses: mraurell@ub.edu, martaraure@gmail.com (M. Raurell-Torredà).

¹ Members of the IMS Group -Es are specified in Appendix A.

² The members of the MOviPre Group are specified in Appendix B.

IMS-Es and BMI [r(95%CI)=-.112((-0.232)-(0.011))], weight [r(95%CI)=-.098((-0.219)-(0.026))], Charlson [r(95%CI)=-.122((-0.242)-(0.001))] and Barthel [r(95%CI)=-.037((-0.160)-(0.087))] and no differences between sexes (p = .587) or BMI categories (p = .412). *Predictive validity*: moderate and significant correlations with post-ICU hospital stay [r(95%CI)=-.442((-0.502)-(-0.377))] and physical component of SF-12 (PCS) [r(95%CI) = .318(.063-.534)]; patients without active mobilisation in ICU increased risk of hospital mortality [OR(95%CI) = 3.769(1.428-9.947)]. *Interobserver reliability*: very good concordance between nurses [CCI (95%CI) = .987(.983-.990)] and nurse-physiotherapist [CCI (95%CI) = .963(.948-.974)]. *Sensitivity to change*: small effect on discharge from ICU (d = .273) and moderate effect at 3 months after hospital discharge (d = .709). Minimal difference: 2-point difference cut-off point, 91.1% sensitivity and 100.0% specificity.

Conclusions: The IMS-Es is useful, valid and reliable for implementation by ICU nurses and physiotherapists in assessing the mobility of critical patients.

© 2020 Sociedad Española de Enfermería Intensiva y Unidades Coronarias (SEEIUC). Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Cuidados intensivos;
Movilización precoz;
Debilidad muscular;
Estudio de validación;
Validez;
Fiabilidad;
Sensibilidad

Adaptación y validación de la *UCI Mobility Scale* en España

Resumen

Objetivo: Adaptar la *ICU Mobility Scale* (IMS) al ámbito de las unidades de cuidados intensivos (UCI) de España y evaluar las propiedades métricas de la IMS versión española (IMS-Es).

Método: Estudio descriptivo de carácter métrico desarrollado en dos fases. Fase 1, adaptación al español de la IMS mediante equipo de enfermeras y fisioterapeutas (traducción, piloto, retrotraducción y acuerdo). Fase 2, análisis de propiedades métricas (validez convergente, divergente y predictiva, fiabilidad interobservador, sensibilidad y diferencia mínima importante) de la IMS-Es. Se registraron características de los pacientes (Barthel, Charlson, IMC, sexo), nivel de sedación/agitación (RASS), estancias en UCI y hospital, supervivencia, calidad de vida (SF-12), debilidad muscular (MRC-SS) y movilidad (IMS-Es) en los pacientes del estudio multicéntrico nacional MOViPre.

Resultados: Tras obtener la IMS-Es, se implementó en 645 pacientes de 80 UCI españolas entre abril y junio de 2017. *Validez convergente*: moderada correlación entre IMS-Es y MRC-SS (r=0,389; p<0,001) y comparación significativa entre grupos con y sin debilidad adquirida en la UCI (p<0,001). *Validez divergente*: no correlación entre IMS-Es e IMC [r(IC95%)=-0,112((-0,232)-(0,011))], peso [r(IC95%)=-0,098((-0,219)-(0,026))], Charlson [r(IC95%)=-0,122((-0,242)-(0,001))] y Barthel [r(IC95%)=-0,037((-0,160)-(0,087))] y sin diferencias entre sexos (p=0,587) ni categorías de IMC (p=0,412). *Validez predictiva*: moderadas y significativas correlaciones con estancia en hospital post-UCI [r(IC95%)=-0,442((-0,502)-(-0,377))] y componente físico del SF-12 (PCS) [r(IC95%)=0,318(0,063-0,534)]; pacientes sin movilización activa en UCI mayor riesgo de mortalidad hospitalaria [OR(IC95%)=3,769(1,428-9,947)]. *Fiabilidad interobservador*: muy buena concordancia entre enfermeras [CCI(IC95%)=0,987(0,983-0,990)] y entre enfermera-fisioterapeuta [CCI(IC95%)=0,963(0,948-0,974)]. *Sensibilidad al cambio*: efecto pequeño al alta de UCI (d=0,273) y moderado a los 3 meses del alta hospitalaria (d=0,709). *Diferencia mínima importante*: punto de corte de la diferencia de 2 puntos, sensibilidad 91,1% y especificidad 100,0%.

Conclusiones: La IMS-Es es útil, válida y fiable para ser implementada, por enfermeras de UCI y fisioterapeutas, al valorar la movilidad de los pacientes críticos.

© 2020 Sociedad Española de Enfermería Intensiva y Unidades Coronarias (SEEIUC). Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

What is known, what does this paper contribute?

To assess the physical function of the intensive care patient and monitor their evolution during their ICU stay validated tools must be used for this population group and with the appropriate metric properties. The *ICU Mobility Scale* (IMS) is a scale which assesses mobility in critically ill patients with good metric properties. This study aims to adapt the IMS to the Spanish context and validation.

Practice implications

A valid and reliable scale has been obtained which may be used in the assessment of mobility for critically ill patients in Spain, both by nurses and by physiotherapists. Thus the language between both professions is standardised in the assessment of the degree of activity of the patients, promoting the development and implementation of individualised activity to prevent ICU-acquired weakness syndrome.

Introduction

Advances in critically ill patient interventions over the last 20 years has made it possible to increase survival after discharge from the intensive care unit (ICU),¹ and the aim of care therefore currently centres upon improving the quality of life of patients after admission to the ICU and to hospital.²

Notwithstanding, post-ICU syndrome is a relatively frequent sequela among patients who survive the ICU. It is defined as the physical, functional and cognitive loss of patients who survive the ICU, and is the cause of 47% readmissions or deaths one year after discharge. Even in the best of cases, it affects the capacities and skills of the patients in their return to the workplace.^{3,4}

One of the most recently studied aspects of the post-ICU syndrome is ICU-acquired muscle weakness (ICUAW), which may be diagnosed between 26% and 65% of patients treated with mechanical ventilation (MV) between 5 and 7 days respectively.^{5,6} ICUAW includes clinical symptoms of myopathy, polyneuropathy and neuro-myopathy, as well as weakness and loss of muscle mass relating to the critical pathology without other explanatory aetiology.

Consequently, validated tools of measurement are required to assess the physical and functional capacity of the critically ill patient in the ICU and to monitor their evolution during their stay and when they return to the community, to be used in our cultural context, with appropriate psychometric properties for the critically ill patient population.⁷⁻⁹

These tools are classified into those which measure muscle mass (anthropometry, bioimpedance, ultrasonography), muscle weakness (manually tested muscle with the Medical Research Council [MRC-SS] or dynamometer and physical function, with this dimension being the one with the most developed tools but fewest appropriately validated. The Chelsea critical care physiotherapy (CPAx), the Physical

function in intensive care test (PFIT) and the ICU Mobility Scale (IMS)¹⁰ are outstanding as the best due to their psychometric qualities

The latter, the IMS,^{11,12} was created to replace the 6 minute walking test, not applicable for the critically ill patient^{8,9} and the only one which aims to standardise the language of nurses and physiotherapists when they describe patient mobilisation during ICU stay. A limitation of many studies is that they assess the effectiveness of early mobilisation in the ICU, but they do not use a validated mobility scale to define the different degrees of activity which are achieved by the patients,¹³⁻¹⁶ thereby hindering comparison between the different studies that assess efficacy of mobility to prevent ICUAW, shorten ICU and hospital stay or prevent death.

Since the IMS has been validated in the critically ill patient, but in the United Kingdom, the aim of this study was to perform a cross-cultural adaptation of the *ICU Mobility Scale* to the Spanish intensive care area and to assess the metric properties of this Spanish version.

Method

A descriptive metric study was conducted in two phases: phase 1, adaptation into Spanish of the *ICU Mobility Scale*; phase 2, analysis of the metric properties of the Spanish version of the scale.

Phase 1. Cross-cultural adaptation

The aim of adaptation into Spanish was to achieve equivalence in the tool at conceptual semantic level, technical content and criterion in a language which differed from that of the original scale.¹⁷

The *ICU Mobility Scale* (IMS) [Appendix C supplementary material] is a scale that contains 10 items which range from 0 (no mobility) to 10 (walks unaided), and which some authors¹⁸ have classed in a binary manner (< 4 passive/active mobilisation in bed and \geq 4 active mobilisation outside bed).

The Spanish adaptation of the IMS was performed in four stages, following different techniques in each (Fig. 1):

Stage one: translation of the IMS and unification for obtaining the first version of the scale into Spanish

The translation from English into Spanish was made by three bilingual health specialist translators who worked independently and whose mother tongue was Spanish. They were given the original version of the tool, together with a brief explanation of its characteristics and uses. Three translations of the tool were obtained into Spanish. After this a review committee was created, formed by two expert nurses and one physiotherapist in the ICU (members of the study research team, with a high level of English) to measure the semantic equivalence of these three versions of the scale translated into Spanish. In the review committee translations were combined, and an initial version of the Spanish IMS was created (IMS-Es-v1).




Figure 1 Process of cross-cultural adaptation of the *ICU Mobility Scale (IMS)*.

Stage two: pilot study

The relevance and comprehensibility of each item of this initial version of the IMS-Es were assessed by 5 nurses and 5 physiotherapists with over 5 years of experience in intensive care. Relevance was determined by a Likert scale in which each item was given a score between 1 (not relevant at all) and 4 (highly relevant). Qualitative appraisals were also collected from the nurses and physiotherapists on each of the items. Text comprehensibility was assessed as bad, acceptable or good.

With this pilot test assessment time was also calculated. Each professional measured the time used in scale application.

With consideration of all contributions, the review committee produced the second version of the IMS-Es (IMS-Es-v2).

Stage three: back-translation of the IMS-Es

A back-translation or inverse translation was made from Spanish into English by three independent, health specialist bilingual translators, whose mother tongue was English and who were aware of the IMS scale proposal but not the original version. Justification for veiling the original version was to ensure a translation which had not been contaminated by previous reading of the items. Each one of

them did an independent translation from the second version of the IMS-Es. Following this, the review committee, in keeping with the previous procedure, combined the three inverse translations, creating a new version of the IMS into English.

Stage four: correlation of the scales in English

The author of the original scale assessed the correspondence item by item between the original version and that obtained from the inverse translations. They assessed the equivalence of content, syntax, technique, criterion and concept of the items as good, appropriate or bad. After this stage the final version was obtained from the ICU Mobility Scale in Spanish (IMS-Es) (Table 1).

Phase 2. Metric validity and reliability study

This phase took place during the months of April and June 2017 in the participant units of the national Spanish multi-centre study on early mobility (MOviPre).¹⁹

Study sample

This included patients in the ICU 48 hours prior to the initiation of invasive mechanical ventilation (IMV).

Table 1 ICU Mobility Scale Spanish version (IMS-Es).

Classification	Definition
0. Immobile (lying on the bed)	Staff mobilise or turn the patient around in bed, but the patient does not actively move
1. Exercises in bed (lying down or half sitting up)	Any activity in bed including turning on side, raising head, active exercises, cycle ergometer and active-assisted exercises, but does not get out of bed or sit on the edge of the bed.
2. Passive mobility to chair (no standing up)	Passive transfer to chair (crane, passive elevation, sliding) without standing up or sitting on the edge of the bed.
3. Seated on the edge of the bed	Active sitting up on the edge of the bed with some control of trunk, with or without staff help
4. Standing up	Supports own weight in standing up (with or without staff assistance, standing frame or raiser)
5. Transfer from bed to chair	Capable of transferring to chair taking steps or dragging feet. This involves active transfer of weight from one leg to the other to reach chair. If the patient has stood up with staff assistance or a medical device, they must walk to the chair without help (not including the movement with the standing frame)
6. Walking in the same place (next to bed)	Capable of walking in the same place picking up their feet alternately (must be able to go 4 steps, two with each foot), with or without aid
7. Walking with the help of 2 or more persons	Walks away from the bed/chair walking at least 5 metres with help from 2 or more people.
8. Walking with the help of one person	Walks away from the bed/chair walking at least 5 metres with help from one person
9. Walking alone with the help of a walking frame	Walks away from the bed /chair walking with the help of a walking frame but without help from another person. In people in wheelchairs this level of activity includes autonomously walking at least 5 metres away from the bed/chair
10. Walking without the help of a walking frame	Walks away from the bed/chair walking at least 5 metres without help from a walking frame or another person

The following patients were not included: those with a main or secondary diagnosis on entry of neuromuscular pathology (myasthenia gravis, Guillain-Barré syndrome, sarcopenia), inability to walk prior to admission (if they walked with a stick or walking frame they were included), admission for stroke or cerebral vascular accident), pregnant women, major burn patients, underage, re-admission to the ICU or transfers to the ICU from other hospitals. Patients who had previously suffered from particular difficulty in mobility were also excluded (absence of limbs *de novo*, users of orthopaedic devices) and those with a body mass index (BMI) over 35.

Exclusion criteria of the study from the clinical histories were Life Support Limitation (LSL) and patients who were alert but incapable of following simple verbal instructions. Patient withdrawal from the study was understood to be when they did not give their consent or they withdrew their consent during the study period and those who were transferred to another hospital intubated, because they were unable to continue with the follow-up. Approval was obtained from all Ethics Committees and from the Clinical Research departments of the participant centres. Data collected by the researcher of the centre were processed

using a user-protected and password database, coding the hospital and patient, ensuring patient confidentiality of all patients in the study.

Type of sample

Convenience sampling during recruitment phase of the MOvipre¹⁹ study to include a minimum of 192 patients, according to the original validation of the IMS scale.¹¹ Calculation of the sample (760 patients) was based on the incidence of ICUAW, of 46% according to the systematic review of Stevens et al.,²⁰ with an estimated standard error of 3 and foreseeable losses of 10%.

Study variables

Patient characteristics: Barthel index prior to admission, Charlson comorbidity index, weight and body mass index, sex. Level of agitation-sedation measured daily with the Richmond Agitation Sedation Scale. Hospital stay after discharge from the ICU and survival on hospital discharge. The ICU Mobility Scale (IMS-Es) score was measured by nursing shifts during the whole stay in the ICU and the Medical

Research Council Scale sum score (MRC-SS) was measured when the patient woke up for the first time during their stay in the ICU and then consecutively every 7 days until discharge from the ICU and score on the quality of life scale (SF-12) of the physical (PCS) and mental (MCS) components, prior to admission in the unit (direct interview with the patient) and 90 days after hospital discharge (over the phone).

Tools of measurement

- Barthel index.²¹ Tool for assessing physical function. The maximum score is 100 points and the patient is considered to be dependent (with different degrees of dependence) if they score 60 or less.
- Charlson comorbidity index.²² Ten-year life expectancy evaluation system, according to the comorbidities of the patient on admission and adjusted to age. Scores range between 0 and 33, indicating the highest scores for the greatest severity in chronic illness.
- Body mass index (BMI), weight in kilograms relating to the height in centimetres. Measured on admission to the unit. Considered as low weight (BMI < 18.5), normal weight (BMI between 18.5 and 24.99), overweight (BMI between 25 and 29.99) and obese (BMI \geq 30).
- *Richmond Agitation Sedation Scale* (RASS).²³ a scale developed and validated to assess sedation and agitation of critically ill patients. It consists of 10 points with 4 levels of agitation/sedation (+4 combative and +1 anxious) and 5 levels of sedation (−1 sleepy and −5 very deep sedation). Level 0 indicates that the patient is calm and alert.
- *Short form 12-item health survey* (SF-12).²⁴ Questionnaire on health-related quality of life. Comprises 12 items. It assesses the degree of well-being and functional ability of people over 14, defining a positive and negative status of physical (PCS) and mental health (MCS), through 8 dimensions.
- *Medical Research Council Scale Sum score* (MRC-SS) in keeping with the assessment protocol described by Vane et al.²⁵ it measures muscle strength, in which each muscle group scores between 0 and 5. There are 12 muscle packages and possible scores ranging from 0 to 60. It is considered that the patient presents with clinical symptoms of ICUAW when the score is lower than 48.

Assessment of the metric properties

Validity

Validity indicates whether the information collected by the scales is genuinely what is to be measured.²⁶ For this the following was considered:

Concurrent or convergent validity. The level of agreement between constructs related to one another is valued. The tool to be validated (IMS-Es) has been related to that of reference (MRC-SS), with both being administered by nurses and physiotherapists, respectively, the same day and time each week. Scores obtained in the MRC-SS assessment were categorised, according to the implied diagnosis of ICUAW (MRC-SS < 48) or discarded (MRC-SS \geq 48). The Spearman correlation (intensity of lineal correlation) was calculated

between the IMS-Es and MRC-SS, with weak correlation being considered to be scores under .30; moderate between .30 and .59, and strong scores above .59.²⁷ Means and interquartile ranges were compared using the Mann-Whitney U-test, [P25-P75] for IMS-Es with relationship with the two categories of the MRC-SS.

Divergent validity. The degree of non correlation between variables which hypothetically bore no relationship with that measured by the new instrument were assessed. The last IMS-Es assessment was correlated simultaneously with the MRC-SS assessment, with body mass index, weight, the Barthel index and the Charlson index. They were also compared with sex and classified BMI. The Spearman correlation was calculated between the IMS-Es and the BMI, weight, Barthel index and Charlson comorbidity index and they were compared, using the Mann-Whitney U-test, medians and interquartile range [P25-P75] for IMS-Es in relation to the patient's sex and classified BMI.

Predictive validity. Capacity of a tool to predict an event. Analysis of the IMS-Es was performed with the SF-12 quality of life questionnaire, adjusted to age, duration of post-ICU hospital stay and hospital mortality. The IMS-Es was stratified according to the best mobility during ICU admission, and passive/active mobility in bed (IMS-Es < 4) or active mobility outside bed (IMS \geq 4), and the SF-12 quality of life questionnaire was analysed with scores obtained from the questionnaire at 90 days and with the differences in scores between the two times the questionnaire was applied (prior to admission and on discharge from the ICU). The Spearman correlation was calculated between the best IMS-Es during stay in the ICU with post-ICU hospital stay and the difference in scores between SF-12 prior to hospital admission and after 90 days on discharge home, both in the physical (PCS) and mental (MCS) components. The risk of dying in hospital for ICU survivors was calculated, according to the best IMS-Es during ICU stay (categorised in passive/active mobility in bed [IMS-Es < 4] or active mobility outside bed [IMS-Es \geq 4]), using the chi-square test. The categorized IMS-Es was also compared, through the Mann-Whitney U test with the difference of SF-12 prior to admission and 90 days after discharge.

Reliability

*Interobserver reliability*²⁶ Degree of concordance between two or more observers. Scores obtained from the IMS-Es research team nurses and between them and physiotherapists were compared. The maximum level of mobility using direct observation was assessed, at the same time but independently. The scores were not contrasted between observers. Both nurses and physiotherapists had over 5 years experience in the ICU. For comparisons, the intraclass correlation coefficient (ICC) was used, establishing a 95% confidence interval. Accepted ICC scores were between 0 and 1, with scores under .31 indicating nill concordance; between .31 and .5, mediocre concordance; between .51 and .7, moderate; between .71 and .9, good and above .9 very good concordance.²⁸ Total concordance was obtained from the sum of the tables where observer scores coincided, with assessment being measured using the corrected kappa index. Poor concordance was considered to be scores under .20; weak concordance between .21 and .40; mod-

Table 2 Overall change assessment scale.

-7	Terrible performance	
-6	Much worse	[3,0]Substantial change
-5	Worse performance	
-4	Moderately worse	
-3	Somewhat worse	[1,0]Minor change
-2	A bit worse	
-1	Almost no changes, just a tiny bit worse	[2,0]No change
0	No changes	
+1	Almost no changes, just a tiny bit better	
+2	A bit better	[1,0]Minor change
+3	Somewhat better	
+4	Moderately better	[3,0]Substantial change
+5	Better performance	
+6	High performance	
+7	Maximum performance	

erate between .41 and .60; good between .61 and .80 and very good concordance over .81 and 1.²⁹ The Spearman coefficient measured observation correlation.

Sensitivity²⁶

Sensitivity to IMS-Es change was assessed in patients who were discharged from hospital and with over 2 days of study inclusion. Scale scores were analysed at different times throughout stay, and size effect and the percentage of patients without change were analysed between the different moments assessed.

Change over time and size effect were assessed using the significance of change in the IMS-Es at three times: on study inclusion, on discharge from the unit and the day in-between. For the patients whose quality of life was assessed 3 months after hospital discharge, the three assessment times were: on study inclusion, on discharge from the ICU and 3 months after hospital discharge. The Wilcoxon signed rank test was used for this, comparing the differences of the medians (interquartile range [IQR]) of the IMS-Es between the first two moments and between the second. Size effect (d) was calculated using the formula $d = Z / \sqrt{n}$. Scores lower than .49 indicate a small size effect; from .5 to .79, that of moderate magnitude and high as equal to or above .8.³⁰ The comparisons between the proportions of patients who showed no change between both moments were assessed using the chi-square test.

To assess the *floor and ceiling effect* the proportion of patients with minimal scores was determined (0 points) and the maximum (10 points) in admission and discharge from the ICU. Floor and ceiling effects under 15% were considered acceptable.

Minimal important difference

This is the smallest difference considered to be clinically relevant for assessing a change in patient management. This was considered the minimal relevant change in level of mobility to assess a change in the rehabilitation programme established by the physiotherapist for each patient. Two methods of analysis was used: a) an external indica-

tor (anchor based method) to analyse the differences of patients by grouping them according to change and show the magnitude of this change over time,³¹ and b) based on distribution, supported by statistics and metric properties of the measurements, to determine the slightest change which could be detected by the tool. The minimal important difference was calculated in live patients discharged from the ICU.

With the anchor based method, when the patient was discharged from the ICU, a research team nurses used a scale from -7 to 7 (Table 2) to record the overall change in mobility, through the IMS-Es recordings at the inclusion of the study and discharge from the ICU.³² Scores of 0-1 were considered as no change, 2-3 as minor changes and 4-7 as major changes.³³ The median (IQR) of the change was compared in the three groups (no change, minor changes and major changes) using the del Kruskal-Wallis test. Sensitivity and specificity of the change in the IMS-Es were calculated to discriminate between the patients with (minor or major) changes and the ones without changes, obtaining a receiver operating characteristic curve (ROC).

To estimate the minimal important difference with the distribution based method, standard mean error (SME) and size effect (SE) of the IMS-Es scores at study inclusion and discharge were used. The SME was calculated from standard deviation (SD) of the means of the measurements and the Spearman rho (r) calculated between the nurses scores ($SME = SD \sqrt{(1-r)}$). SE was quantified with SD of the difference in scores on study inclusion and discharge ($SE = .5 * SD$). Sensitivity analysis was completed by excluding patients whose condition worsened, according to the overall mobility evaluation.

Usefulness of the scale³⁴

This refers to financial cost and time used, simplicity, clarity and if previous training was required for use. The calculation of utility derives from the assessments made by the nurses and physiotherapists during the pilot study in the cross-cultural adaptation phase.

Table 3 Patient characteristics.

	All patient n = 645	Alive at ICU discharge n = 483	Alive at hospital discharge n = 450	Alive at hospital discharge and inclusion >2 days n = 437
Age, years, mean (SD)	63 (15)	61 (16)	60 (16)	60 (16)
Sex, female, n (%)	196 (30,4)	151 (31,3)	145 (32,2)	142 (32,5)
BMI, kg/m ² , media (SD)	27 (4)	27 (4)	27 (4)	27 (4)
Barthel, points, mean (SD)	95.5 (10.7)	96.2 (9.6)	96.6 (9.2)	96.5 (9.3)
Charlson, points, media (IQR)	4 (1-6)	4 (0-6)	4 (0-5)	4 (0-5)
Apache II, points, mean (SD)	21 (8)	20.5 (7.8)	20.3 (7.8)	20.3 (7.9)
[0,1-5]Diagnosis on admission, n (%)				
Sepsis	126 (19.5)	97 (20.1)	91 (20.2)	89 (20.4)
Trauma	33 (5.1)	29 (6)	28 (6.2)	28 (6.4)
Neurosurgery	14 (2.2)	10 (2.1)	9 (2)	9 (2.1)
Heart surgery	57 (8.8)	46 (9.5)	45 (10)	44 (10.1)
Other surgery	116 (18)	95 (19.7)	94 (20.9)	91 (20.8)
Overdose	12 (1.9)	11 (2.3)	11 (2.4)	11 (2.5)
Other medical diagnoses	287 (44.5)	195 (40.4)	172 (38.2)	165 (37.8)
[0,1-5]Origin, n (%)				
Home	49 (7.6)	36 (7.5)	35 (7.8)	35 (8)
Hospital ward	289 (44.8)	200 (41.4)	184 (40.9)	177 (40.5)
Emergency services	255 (39.5)	205 (42.4)	192 (42.7)	187 (42.8)
Other hospital	52 (8.1)	42 (8.7)	39 (8.7)	38 (8.7)
Stay in ICU. Days, mean (IQR)	14 (9-23)	13 (8-22)	13 (8-22)	13 (8-23)
RASS inclusion, points, mean (IQR)	-3 (-1 a -4)	-3 (-1 a -4)	-3 (-1 a -4)	-3 (-1 a -4)
RASS discharge from ICU, points, mean (IQR)	0 (0 a -3)	0 (0-0)	0 (0-0)	0 (0-0)
Patients who develop ICUAW, n (%)	278 (43.1) ⁺	247 (51.1) ⁺⁺	232 (51.6) ⁺⁺⁺	229 (52.4) ⁺⁺⁺⁺
Stay in hospital after discharge from ICU, days, mean (IQR)	9 (0-19)	13 (7-25)	13 (7-25)	14 (7-26)
Stay in hospital, days, means (IQR)	29 (18-48)	32 (20-52)	32 (20-52)	33 (2-53)
[0,1-5]Destination on ICU discharge, n (%)				
Hospital ward	471 (73)			
Other centre	12 (1,9)			
Death	162 (25.1)			
[0,1-5]Destination at hospital discharge, ^a n (%)				
Home		364 (75.4)	364 (75.4)	352 (80.5)
Other centre		76 (15.7)	76 (15.7)	75 (17.2)
Death		33 (6.8)	-	-
[0,1-5]SF-12 prior to admission, points, mean (IQR) ^b				
Physical health (PCS)		47.6 (35.9-54.33)		
Mental health (MCS)		46.98 (35.99-54.39)		
[0,1-5]SF-12 90 days after discharge, points, mean (IQR) ^b				
Physical health (PCS)		42 (33.75-50.92)		
Mental health (MCS)		50.07 (39.78-56.72)		

SD: standard deviation; ICUAW: ICU-acquired muscle weakness; BMI: body mass index; RASS: Richmond Agitation Sedation Scale; IQR: interquartile range.

⁺169.

⁺⁺45.

⁺⁺⁺38.

⁺⁺⁺⁺36 lost patients.

^a10 lost cases.

^bon 57 patients.

Variables are described as median and interquartile range (IQR) or mean and standard deviation (SD) for the quantitative variables (depending on the parametric behaviour of them). For qualitative variables absolute (n) and relative (%) frequencies were used. The normality of the variables was assessed using the Kolmogorov-Smirnov test. For data analysis the SPSS Statistics for Windows (version 23.0 IBM Corp; U.S.A.) programme and the Stata® (version IC14, StataCorp LLC; U.S.A.) programme were used.

Results

Phase 1. Cross-cultural adaptation

Developed between the months of January and February 2017. In the pilot test phase of the IMS-Es-v1 each item scored between 1 (not relevant at all) and 4 (highly relevant). Sixty six per cent of evaluations determined that the items had a relevance of 3 or 4. We found there were differences between the assessments of the nurses and those of the physiotherapists; essentially in the lowest score of relevance (relevance 1: 26% of nurses vs 0% of physiotherapists; $p < .001$) and in the highest score (relevance 4: 31% of nurses vs 62% of physiotherapists; $p = .001$). The items regarded as less relevant by 60% of nurses were those in which the patients carried out active mobility outside bed ($IMS-Es \geq 4$), compared with only 20% of physiotherapists.

The time taken to apply the scale was a median of 2'30'' (IQR: 1'45''-4'15''), with no relevant differences found between professionals (nurses vs physiotherapists: 2' [1'30''-4'30''] vs 3' [1'30''-4'20'']).

The item to item agreement of the original scale with that resulting from unification of the back translations or inverse translations was assessed as good in all of its items. After the adaptation process (Fig. 1) we obtained the IMS-Span (MS-Es) (Table 1) scale.

Phase 2. Validity and reliability metric study

The Spanish version of the IMS (Table 1) was implemented during the months of April to June 2017 in 645 patients from the 80 Spanish ICU participating in the MOvipre study.¹⁹ These 645 patients provided 10,133 daily recordings in the ICU. Patient characteristics and measurements of the IMS-Es and MRC-SS are contained in Tables 3 and 4, respectively.

Validity

Convergent validity. Of the 645 patients included, MRC-SS was only able to be assessed in 475; the other patients did not become participatory. Out of these, 253 patients were assessed with MRC-SS on more than one occasion. The Spearman correlation coefficient, measured between the last MRC-SS and IMS-Es assessment on the same day, was .389 ($p < .001$). Among the patients who developed ICUAW during their stay, the Spearman correlation coefficient calculated was .475 ($p < .001$). The comparison of means (IQR) from the IMS-Es evaluations between groups according to ICUAW (MRC-SS < 48) or non ICUAW (MRC-SS \geq 48) in the last eval-

Table 4 Mobility scores and MRC-SS.

[0,1-2]Mobility (IMS-Es)	
	Patients (n = 645)
Mobility on day of inclusion, points, mean (IQR)	0 (0-0)
Better mobility during admission, points, mean (IQR)	2 (1-4)
Mobility on day of last MRC-SS ^a , points, mean (IQR)	2 (2-5)
Mobility at discharge, points, mean (IQR)	2 (0-4)
	Measurements (n = 10.133)
Level of mobility, n (%)	
< 4	9.232 (91)
\geq 4	901 (9)
[0,1-2]Weakness (MRC-SS)	
	Patients (n = 475)
First MRC-SS, points, mean (IQR)	44 (33-52)
Last MRC-SS ^a , points, mean (IQR)	49 (41-55)
	Measurements (n = 929)
MRC-SS, n (%)	
< 48	518 (55.8)
\geq 48	411 (44.2)
IQR: interquartile range.	
^a On 253 patients.	

uation of the MRC-SS was statistically significant ($p < .001$) (Table 5).

Divergent validity. A weak and negative correlation was observed between IMS-Es and weight ($r = -.098$), BMI ($r = -.112$), the Charlson index ($r = -.122$) and the Barthel index ($r = -.043$). There were no significant differences between the medians (IQR) of the IMS-Es of men vs women ($p = .587$), or between the medians (IQR) of classified BMI ($p = .412$) (Table 5).

Predictive validity. A significant and negative correlation was observed between the best IMS-Es obtained during admission to the ICU and stay in the hospital post-ICU. A significant correlation was also observed in this case positive, between the best IMS-Es and the difference in the physical component of the SF-12 questionnaire, measured prior to admission and 90 days afterwards; with the mental component of the SF-12 we observed no correlation. A significant difference was obtained in the percentage of patients who died in the hospital (on discharge from the ICU), between those who did not have active mobility outside bed during their stay in the ICU ($IMS-Es < 4$) vs those who did actively move ($IMS \geq 4$) (28/291 vs 5/182; OR [95% CI]: 3.769 [1.428-9.947]; $p = .004$). Although no significant differences were found in the difference between the physical and mental components of the SF-12 between patients with passive/active mobility in bed vs active mobility out-

Table 5 Results of the validation analysis.

	Test	Variable IMS	Comparison variables	n	Results	p	Concordance/correlation	
Convergent validity	Spearman	IMS-Es ^a	Last MRC-SS	253	r (95% CI): .389 (.279-.489)	< .001	Moderate correlation	
	U Mann-Whitney		Last MRC-SS < 48	108	Md (IQR): 2 (1-2.75)	< .001		
Divergent validity	Spearman		MRC-SS last \geq 48	145	Md (IQR): 4 (2-5)		No correlation	
			BMI	253	r (IC95%): -.112 (-.232 to .011)	.074		
			weight	253	r (IC95%): -.098 (-.219 to .026)	.120		
			Charlson	253	r (IC95%): -.122 (-.242 to .001)	.052		
	Mann-Whitney U test		Barthel	253	r (IC95%): -.037 (-.160 to .087)	.559		
			Males	166	Md (IQR): 2 (2-5)	.587		
			Females	87	Md (IQR): 2 (2-5)			
Predictive validity	Spearman	Better IMS-Es during admission	Low weight	7	Md (IQR): 4 (2-5)	< .001	Moderate correlation	
			Normal weight	87	Md (IQR): 3 (2-5)			
			Overweight	97	Md (IQR): 2 (2-5)			
			Obesity	62	Md (IQR): 2 (1-5)			
			Stay from ICU discharge up to hospital discharge	639	r (IC95%): -.442 (-.502 to -.377)			
	Chi-square test		SF12. Differentia PCS	57	r (IC95%): .318 (.063-.534)	.016	Moderate correlation	
			SF12. Differentia MCS	57	r (IC95%): .157 (-.108 to .401)	.244		
			Hospital mortality	473	9.62% vs. 2.75%	.004		
			Mann-Whitney U test	SF-12 90 days (PCS)	32	OR (IC95%): 3.769 (1.428-9.947)		.085
					25	Md (IQR): 38.48 (32.19-48.10)		
SF-12 90 days (MCS)	32	Md (IQR): 43.35 (34.99-54.07)						
Interobserver reliability	Coefficient of intraclass correlation	IMS-Es nurse 1	IMS-Es nurse 2	254	Md (IQR): 49.42 (41.84-56.23)	< .001	Very good concordance	
			IMS-Es physiotherapist	133	Md (IQR): 52.92 (36.66-59.09)			
		IMS-Es nurse 2	IMS-Es nurse 1	254	CCI (IC95%): .987 (.983-.990)			
			IMS-Es physiotherapist	133	CCI (IC95%): .963 (.948-.974)			

Table 5 (Continued)

	Test	Variable IMS	Comparison variables	n	Results	p	Concordance/correlation	
Sensitivity	Kappa corrected	IMS-Es nurse 1	IMS-Es nurse 2	254	.724 (.660-.789)	< .001	Good concordance (78% agreements)	
			IMS-Es nurse	IMS-Es physiotherapist	133	.673 (.580-.766)	< .001	Good concordance (74% agreements)
	Spearman	IMS-Es nurse 1	IMS-Es nurse 2	254	r (IC95%): .948 (.934-.959)	< .001	Strong concordance	
			IMS-Es nurse	IMS-Es physiotherapist	133	r (IC95%): .940 (.916-.957)	< .001	Strong concordance
	Wilcoxon range signals	IMS-Es inclusion	IMS-Es individual mean of ICU stay	IMS-Es ICU discharge	427	Md (IQR): 0 (0-0)	< .001	Minor effect
					52	Md (IQR): 1 (0-2)	d = .273	
					52	Md (IQR): 2 (1-5)	< .001	Moderate effect
					52	Md (IQR): 0 (0-0)	< .001	Moderate effect
	Minimal important difference	Kruskal-Wallis	Difference of IMS-Es between admission and discharge	No change	483	Md (IQR): 1 (0-1)	< .001	
						Minor change	Md (IQR): 2 (2-2)	
					Major change	Md (IQR): 5 (4-5)		

^aLast IMS-Es simultaneously assessed with the last MRC-SS.

MCS: mental component of the SF-12; Md: median ; PCS: physical component of the SF-12; IQR: interquartile range.

side bed, it was observed that patients with active mobility outside bed improved by 5 and 3 points, respectively, in both components (Table 5).

nurse to nurse peer and in the nurse to physiotherapist peer assessments (Table 5).

Inter-observer reliability

Two hundred and fifty four peer assessments were simultaneously made by two ICU nurses and 133 peer assessments by one ICU nurse and one physiotherapist. Very good concordances and strong correlations were found both in the

Sensitivity

Size effect in IMS-Es changes between study inclusion and the intermediate point and between this intermediate point and discharge were minor (d = .273) (Table 5). 52.7% of patients presented with an improvement between the day of the inclusion and the intermediate day; 66.3% improved




Figure 2 Difference of mobility between groups according to the overall change assessment scale.

from the intermediate day to discharge from the unit ($p < .001$).


Size effect observed in the comparison of the medians of the differences between the moments of inclusion and ICU discharge and ICU discharge and 3 months after hospital discharge were moderate ($d = .709$) (Table 5). 90.4% of patients improved between inclusion and ICU discharge and 100% improved from hospital discharge to 3 months after this ($p = .056$).

At inclusion the percentage of patients with a 0 score was 76.8%, whilst the percentage of patients with a 10 score was .2%. On discharge from the ICU the IMS-Es presented acceptable scores (<15%) both for the floor and ceiling effect, with percentages of 6.8 and 1.4%, respectively. On inclusion 60.5% of patients had a sedation level (measured with the *Richmond Agitation Sedation Scale*) of -3 or under (RASS, median [IQR] = -3 [-1 to -4]); on discharge there were .9% who had a RASS of ≤ -3 (RASS, median [IQR] = 0 [0 to 0]).

Minimal important difference

Minimal important difference according to the anchor based method. The median (IQR) of IMS-Es on admission of the 483 patients who survived ICU was 0 (0-0) and 2 (1-5) on discharge; the median of the difference of mobility between ICU admission and discharge was 2 (1-4). According to the assessment scale of overall change (Table 2), no change was observed in 147 patients (30.4%); change was minor in 167 (34.6%) and major in 169 (35.0%). Comparison between medians (IQR) of the difference of mobility between admission and discharge between the three groups is significant (Fig. 2). The area below the ROC curve was .98 (95% CI: .97-.98) (Fig. 3). Analysis determined a cut-off point of 2 on the IMS-Es scale as a clinically relevant symptom, with 91.1% sensitivity and 100.0% specificity. In the sensitivity analysis, with the exception of the 4 patients whose mobility worsened between inclusion and discharge, the results obtained were not modified.

Minimal important difference according to distribution. From the standard deviation (SD) of the IMS-Es at time of inclusion (.779) and discharge (2.079), mean standard error (MSE) was .178 and .474, respectively. The size effect calculated from SD of difference (2.039), was 1.020. In sensitivity



Cut-off point	Sensitivity, % (IC95%)	Specificity, % (IC95%)	Efficacy*, % (IC95%)	LH- (IC95%)	AUC (IC95%)
2	91.1 (87.5–93.7)	100.0 (97.5–100.0)	93.8 (91.3–95.6)	0.089 (0.063–0.126)	0.98 (0.97–0.98)

* Efficacy: proportion of correctly classified cases
 LH-negative likelihood ratio
 AUC: area under ROC curve

Figure 3 Area under ROC curve.

analysis, excluding the 4 patients whose mobility level deteriorated, the MSE at inclusion was .178 and at discharge .472, with an effect size of 1.011?

Scale utility

This scale could be considered usefully bearing in mind the time required to implement it, its low cost and that the nurses and physiotherapists who participated in the pilot study stating that it was an easy scale to apply.

Discussion

This study has led to the adaptation of the IMS scale to the Spanish context and provided a tool which is easy, valid and reliable for nurses and physiotherapists to apply in clinical practice.

The differences observed in the cross-cultural adaptation of the original scale, regarding the relevance of the items assessed by the nurses and physiotherapists, are based on the different skills of each profession. The nurses did not regard high scores as relevant, where the patient walked, because they considered there were few patients who would develop this ability. However, the physiotherapists regard these scores as highly relevant and irrelevant those where the patients remain immobile in bed, which is in keeping with that found in the literature.³⁵⁻³⁷

With regard to the convergent validity, we obtained a moderate correlation with the latest MRC-SS (r [95% CI]: .389 [.279-.489]; $p < .001$), which were lower findings than those obtained in the original scale (r [95% CI]: .64 [.49-.75]; $p < .001$).¹² Similarly, the differences in mobility observed between the group which developed ICUAW and the one which did not are equally significant. It is possible for the patients included in this study were less actively mobilized although they had capacity for it, due to the fact that only 14% of units had mobility protocols,¹⁹ compared with

36.5% of the units in Australia, where the original scale was validated.¹²

Furthermore, another justification for low mobility could be the nurse: patient ratio, which in our environment is 1:2 only in 47.7% of units; 1:3 in 25.6% and up to 1:4 in 3.5% of them.¹⁹

From analysis of divergent validity we obtained similar results to those obtained in the original scale,¹² with an absence of significant correlation with weight and without differences between the sexes. Non comparison of the IMS with the BMI was one of the limitations described in the validation of the original version of the scale; in this version of the IMS-Es we did assess this correlation, and it was not significant considered either as a continuous or categorical variable.

In contrast the IMS-Es scale does have a predictive ability regarding stay and mortality. The patients with the best scores on the IMS-Es during ICU stay have a shorter stay in the hospital following ICU discharge and also non active mobility outside bed carries a higher risk of dying in the hospital. This capacity of the IMS-Es to predict hospital mortality was also observed by Tipping ET al.³⁸ in the original scale.

Regarding quality of life prediction, the IMS³⁸ was unable to demonstrate this validity, but the IMS-Es was. It was proven to have validity regarding the physical component of quality of life 90 days after hospital discharge.

Reliability analysis offers good and very similar concordances to those of the original scale¹¹ (kappa .72 of nurses with senior physiotherapists and .69 with junior physiotherapists) and superior correlations ($r = .77-.80$).¹¹ Wilches et al.³⁹ obtained similar correlations (CCI between .94 y 1) and better concordances (K between .988 and .992), although in this study only the scores of the physiotherapists were considered, similarly to that of Kawaguchi et al.,⁴⁰ which obtained higher correlations between physiotherapists (K [95% CI]: .99 [.98-.99]) in the validation of the Portuguese version of the IMS. This correlation between physiotherapists has not been assessed in this study, because we considered that IMS was created to be used in the ICU area and to standardize language between nurses and physiotherapists.

The high floor effect values (76.8%) at time of inclusion may be explained by the level of sedation, since 60.5% of patients had a deep sedation level. Tipping et al.,¹² in the original scale, also obtained a high floor effect on admission (96%), with RASS median of -4 . The size effect obtained in the change of IMS-Es between inclusion and discharge was minor ($d = .273$) and very much lower than that obtained in the original scale¹² ($d = .8$). This small effect observed would possibly be due to the low mobility of the patients included in the study and because in the original scale the moments of inclusion, discharge and 6 months after hospital discharge were analysed, where the mobility level of all patients was 10. In the IMS-Es validation we took into account the moments of inclusion, discharge and the day in-between both. This penalised us because the level of mobility we observed was not as high. We did obtain a moderate size effect ($d = .709$) in the cohort of patients where the quality of life 3 months after hospital discharge was assessed.

The minimal important difference obtained was between scores of .178 and 2. These scores were below those

obtained on the original scale with the population of Australia and New Zealand,¹² where scores between .89 and 3 were obtained. The reason for these low data again may stem from the lower mobility of the patients in this study. As a result, clinical relevance in the change was obtained with lower scores.

It should be considered that one limitation of the minimal important difference, measured with the external indicator of the anchor based method is that this method is defined as the smallest change in patient evolution that they consider relevant. In the case of critically ill patients it is not possible for the patients to offer their evaluation of the change, which is why we believe it was most appropriate for the nurse to determine it. Also bearing in mind that the MOviPre¹⁹ study included the participation of 80 Spanish ICUs, it was complicated to establish similar criteria to determine the relevance of change, and the evaluation was performed by a single expert ICU nurse, based on the recordings of mobility and bearing in mind age, the Barthel index score on admission, diagnosis on admission, severity and length of ICU stay in days. Although it is true that it may not reflect what patients think, professional evaluation based on clinical data may also be considered a valid method.⁴¹

Conclusions

The scale obtained is useful, valid, and reliable to be used by both ICU nurses and physiotherapists, to evaluate the mobility of critically ill patients and plan personalised activity programmes, to prevent ICU-acquired muscle weakness.

Financing

This study did not receive any financing.

Conflict of interest

The authors have no conflict of interest to declare.

Acknowledgements

The Spanish Society of Intensive Nursing and Coronary Units (SEEIUC) was the study promoter.

Appendix 1. Autores Grupo IMS-Es

Natalia Cámara-Conde, Oscar Peñuelas-Rodríguez, Raquel Herrero-Hernández, M^a Mar Sánchez-Sánchez, M^a Pilar Fraile-Gamo (Hospital Universitario de Getafe, Madrid); Candelas López-López, M^a Jesús Frade-Mera, Noelia Regueiro-Díaz, Luis Fernando Carrasco Rodríguez-Rey, Ignacio Zaragoza-García, Francisco Javier Zarza-Bejarano, Virginia Toribio-Rubio, María Catalina Pérez-Muñoz (Hospital Universitario 12 de Octubre, Madrid); María Acevedo Nuevo, Alejandro Barrios (Hospital Universitario Puerta de Hierro Majadahonda, Madrid); Tamara R. Velasco-Sanz (Hospital Universitario Clínico San Carlos, Madrid); Saúl García-González (Hospital Universitario de Móstoles, Madrid); Emilia Romero de San Pío (Hospital Central de Asturias, Oviedo); Joan-Daniel Martí-Romeu, Eva Blázquez-Martínez,

Alicia San José-Arribas, Sandra Belmonte (Hospital Clinic de Barcelona, Barcelona); Elisabeth Gallart (Hospital Vall d'Hebrón, Barcelona). Ricardo Rodrigues Gomes (Hospital Alvaro Cunqueiro, Vigo, Pontevedra); Antonio Tomás Ríos Cortés (Hospital General Universitario Santa Lucía, Cartagena, Murcia); Roberto Martínez Alejos (Centre Hospitalier Universitaire, Bordeaux), Ana Rodríguez Merino (Royal Brompton and Harefield Hospital Trust, London), Elsa Afonso (Rosie Hospital, Cambridge).

Appendix 2. Autores Grupo MOviPre

Coordinadora Andalucía: María Esther Rodríguez Delgado. Autores: Antonia María Contreras Rodríguez; Ester Oreña Cimiano; Alvaro Ortega Guerrero; María del Carmen Martínez del Aguila; Virginia Rodríguez Monsalve; Carlos Leonardo Cano Herrera; Juan Manuel Masegosa Pérez, de los hospitales Poniente, Virgen de Valme, Quirón, Santa Ana.

Coordinadora Aragón: Delia María González de la Cuesta. Autores: María Inmaculada Pardo Artero; Marta Palacios Laseca; Ana Isabel Cabello Casao; María Belén Vicente de Vera Bellostas; Carmen Pérez Martínez; Sheila Escuder González; Amelia Lezcano Cisneros; Antonio Miguel Romeo; Isabel López Alegre, de los hospitales Clínico Universitario Lozano Blesa, Royo Villanova, Universitario Miguel Servet, Obispo Polanco.

Coordinadora Asturias: Emilia Romero de San Pío. Autores: Helena Fernández Alonso; Lara María Rodríguez Villanueva; Roberto Riaño Suárez, Begoña Sánchez Cerviño, Sergio Carrasco Santos, de los hospitales Universitario Central de Asturias y San Agustín.

Coordinadora Canarias: Alicia San José Arribas. Autores: Miriam González García; Antonio Linares Tavio, del Complejo Hospitalario Universitario de Canarias.

Coordinadora Cantabria: Paz Álvarez García. Autores: Nuria Polo Hernández; Lourdes Gómez Cosío; Isabel Pérez Loza; Ángela Suárez Pérez; Sonia Crespo Rebollo, del Hospital Universitario Marqués de Valdecilla.

Coordinador Castilla La Mancha: Juan Carlos Muñoz Camargo. Autores: Julián García García; César Rojo Aguado; José Gómez López; Laura Sonseca Bartolomé, de los hospitales Universitario de Guadalajara y General de Albacete.

Coordinadora Castilla y León: Alicia San José Arribas. Autores: Sonia del Olmo Nuñez; Patricia García Mazo; Eduardo Siguero Torre; Isabel Muñoz Díez, de los hospitales Universitario Río Ortega y Clínico de Valladolid.

Coordinadora Catalunya: Pilar Delgado Hito. Autores: Mercedes Olalla Garrido Marín; Gemma Marín Vivó; María del Mar Eserverri Rovira; Montserrat Guillen Dobon; Montserrat Aran Esteve; Maribel Mirabete Rodríguez; Albert Mariné Méndez; Silvia Rodríguez Fernández; Joan Rosselló Sancho; Valeria Zafra Lamas; Inmaculada Carmona Delgado; Àngels Navarro Arilla; Gustau Zariquiey Esteve; Angel Lucas Bueno Luna; Cristina Lerma Brioso; Rubén Gómez García; Bernat Planas Pascual; Marta Sabaté López; Ana Isabel Mayer Frutos; Roser Roca Escrihuella; Gemma Torrents Albà; Vanesa García Flores; Joan Melis Galmés; Sandra Belmonte Moral; Montserrat Grau Pellicer; Aintzane Ruiz Eizmendi; Carme Garriga Moll; Esteve Bosch de Jaureguizar, de los hospitales Universitari Vall d'Hebrón, Santa Creu i Sant Pau; Clínic

de Barcelona; Consorci Sanitari de Terrassa; Universitari de Girona Dr. Josep Trueta; Universitari de Bellvitge.

Coordinador Extremadura: Sergio Cordovilla Guardia, Fidel López Espuela. Autores: Lara Mateos Hinojal, María Isabel Redondo Cantos, del hospital Complejo Hospitalario de Cáceres.

Coordinadora Galicia: M^a del Rosario Villar Redondo. Autores: Jesús Vila Rey, Susana Sánchez Méndez; Yolanda García Fernández; María Cristina Benítez Canosa; Mauricio Díaz Álvarez; José Ramón Cordo Isorna; Ángeles Estébez Penín; Gloria Güeto Rial; Esther Bouzas López, de los hospitales Universitario Lucus Augusti, Complejo Hospitalario Universitario de Ourense, Complejo Universitario Santiago de Compostela y Complejo Hospitalario Universitario de Pontevedra.

Coordinadoras Madrid: Susana Arias Rivera, María Jesús Frade Mera y María Jesús Luengo Alarcia. Autores: Noelia Regueiro Díaz; Luis Fernando Carrasco Rodríguez-Rey; María del Rosario Hernández García; Gema Sala Gómez; Javier Vecino Rubio; Saúl García González; María del Mar Sánchez Sánchez; Carmen Cruzado Franco; Beatriz Martín Rivera; Rocío González Blanco; Ana Belén Sánchez de la Ventana; María Luisa Bravo Arcas; Josefa Escobar Lavela; María del Pilar Domingo Moreno; Mercedes García Arias; Inmaculada Concepción Collado Saiz; María Acevedo Nuevo; Alejandro Barrios Suárez; Francisco Javier Zarza Bejarano; María Catalina Pérez Muñoz; Virginia Toribio Rubio; Patricia Martínez Chicharro; Alexandra Pascual Martínez; Sergio López Pozo; Laura Sánchez Infante; Verónica Ocaña García; Daniel Menes Medina; Ana Vadillo Cortázar; Gema Lendínez Burgos; Jesús Díaz Juntádez; María Teresa Godino Olivares; de los hospitales Universitario 12 de Octubre, Universitario de Móstoles, Universitario de Getafe, Universitario La Paz; Universitario Ramon y Cajal; Universitario Clínico San Carlos; Universitario del Sureste; Infanta Leonor, del Henares; Universitario Puerta de Hierro Majadahonda y Universitario Gregorio Marañón.

Coordinador Murcia: Juan José Rodríguez Mondéjar. Autores: Francisco José Martínez Rojo; María Vanessa Ruiz Martínez; Daniel Linares Celdrán; Antonio Ros Molina; Javier Sáez Sánchez; José María Martínez Oliva; Ana Bernal Gilar; María Belén Hernández García; Antonio Tomás Ríos Cortés; Raquel Navarro Méndez; Sebastián Gil García; Juan Sánchez Garre, de los hospitales Universitario Morales Messeguer, Universitario Los Arcos del Mar Menor, Universitario Santa Lucía, Universitario Rafael Méndez, Clínico Universitario Virgen de la Arrixaca y Reina Sofía de Murcia.

Coordinadora Navarra: Miriam del Barrio Linares. Autores: Rosana Goñi Viguria y Raquel Aguirre Santano; de la Clínica Universitaria de Navarra.

Coordinadora País Vasco: M^a Rosario García Díez. Autores: Laura Aparicio Cilla; Mónica Delicado Domingo; César Rodríguez Nuñez; Ane Arrasate López, de los hospitales Universitario de Basurto y Universitario Araba (sede Txagorritxu).

Coordinadora Valencia: Ángela Romero Morán. Autores: Rosa Paños Melgoso; Mónica Yañez Cerón; Amparo Mercado Martínez; Beatriz Martínez Llopis; María Josefa Vayá Albelda; Javier Inat Carbonell; m. Rosario Alcayne Senent; Fátima Giménez García; Eva Cristina Fernández Gonzaga; Laura Febrer Puchol; Senén Berenguer Ortuño; María Pastor Martínez; Dunia Valera Talavera; María José Segrera Rovira;

Yolanda Langa Revert; Maricruz Espí Pozuelo; María Ángeles de Diego; Beatriz Garijo Aspas; María del Rosario Asensio García; José Ramón Sánchez Muñoz; Quirico Martínez Sánchez; Ramón López Mateu, de los hospitales Universitario Dr. Peset Aleixandre, General de Elda, Universitario de la Ribera, Luís Alcanyis de Xàtiva, Clínico Universitario de Valencia, Provincial de Castellón, de Requena, Universitario San Juan, Universitario de la Plana, de Orihuela y Universitario de Elche.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.enfi.2019.10.001>.

References

- Major ME, Kwakman R, Kho ME, Connolly B, McWilliams D, Denehy L, et al. Surviving critical illness: what is next? An expert consensus statement on physical rehabilitation after hospital discharge. *Crit Care*. 2016;20:354.
- Oeyen SG, Vandijck DM, Benoit DD, Annemans L, Decruyenaere JM. Quality of life after intensive care: a systematic review of the literature. *Crit Care Med*. 2010;38:2386–400, <http://dx.doi.org/10.1097/CCM.0b013e3181f3dec5>.
- Herridge MS, Chu LM, Matte A, Tomlinson G, Chan L, Thomas C, et al. Investigators RP, Canadian Critical Care Trials Group. The RECOVER program: disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. *Am J Respir Crit Care Med*. 2016;194:831–44.
- Fan E, Dowdy DW, Colantuoni E, Mendez-Tellez PA, Sevransky JE, Shanholtz C, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. *Crit Care Med*. 2014;42:849–59, <http://dx.doi.org/10.1097/CCM.000000000000040>.
- Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. *Crit Care*. 2015;19:274, <http://dx.doi.org/10.1186/s13054-015-0993-7>.
- De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Groupe de Réflexion et d'Etude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA*. 2002;288:2859–67.
- Hodgson CL, Berney S, Harrold M, Saxena M, Bellomo R. Clinical review: early patient mobilization in the ICU. *Crit Care*. 2013;17:207, <http://dx.doi.org/10.1186/cc11820>.
- Elliott D, Denehy L, Berney S, Alison JA. Assessing physical function and activity for survivors of a critical illness: a review of instruments. *Aust Crit Care*. 2011;24:155–66, <http://dx.doi.org/10.1016/j.aucc.2011.05.002>.
- Tipping CJ, Young PJ, Romero L, Saxena MK, Dulhunty J, Hodgson CL. A systematic review of measurements of physical function in critically ill adults. *Crit Care Resusc*. 2012;14:302–11.
- Parry SM, Granger CL, Berney S, Jones J, Beach L, El-Ansary D, et al. Assessment of impairment and activity limitations in the critically ill: a systematic review of measurement instruments and their clinimetric properties. *Intensive Care Med*. 2015;41:744–62, <http://dx.doi.org/10.1007/s00134-015-3672-x>.
- Hodgson CL, Needham DM, Haines K, Bailey M, Ward A, Harrold M, et al. Feasibility and inter-rater reliability of the ICU Mobility Scale. *Heart Lung*. 2014;43:19–24, <http://dx.doi.org/10.1016/j.hrtlng.2013.11.003>.
- Tipping CJ, Holland AE, Harrold M, Crawford T, Halliburton N, Hodgson CL. The minimal important difference of the ICU mobility scale. *Heart Lung*. 2018;47:497–501, <http://dx.doi.org/10.1016/j.hrtlng.2018.07.009>.
- Berney SC, Rose JW, Bernhardt J, Denehy L. Prospective observation of physical activity in critically ill patients who were intubated for more than 48 hours. *J Crit Care*. 2015;30:658–63, <http://dx.doi.org/10.1016/j.jcrc.2015.03.006>.
- Jolley SE, Moss M, Needham DM, Caldwell E, Morris PE, Miller RR, et al. Acute Respiratory Distress Syndrome Network Investigators. Point Prevalence Study of Mobilization Practices for Acute Respiratory Failure Patients in the United States. *Crit Care Med*. 2017;45:205–15, <http://dx.doi.org/10.1097/CCM.0000000000002058>.
- Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet*. 2009;373:1874–82, [http://dx.doi.org/10.1016/S0140-6736\(09\)60658-9](http://dx.doi.org/10.1016/S0140-6736(09)60658-9).
- Schaller SJ, Anstey M, Blobner M, Edrich T, Grabitz SD, Gradwohl-Matis I. International Early SOMS-guided Mobilization Research Initiative. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. *Lancet*. 2016;388:1377–88, [http://dx.doi.org/10.1016/S0140-6736\(16\)31637-3](http://dx.doi.org/10.1016/S0140-6736(16)31637-3).
- Sousa VD, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. *J Eval Clin Pract*. 2011;17:268–74, <http://dx.doi.org/10.1111/j.1365-2753.2010.01434.x>.
- Brock C, Marzano V, Green M, Wang J, Neeman T, Mitchell I, et al. Defining new barriers to mobilisation in a highly active intensive care unit -have we found the ceiling? An observational study. *Heart Lung*. 2018;47:380–5, <http://dx.doi.org/10.1016/j.hrtlng.2018.04.004>. PMID: 29748138.
- Raurell-Torredà M, Arias-Rivera S, Martí JD, Frade-Mera MJ, Zaragoza-García I, Gallart E, et al. Grupo MOviPre. Grado de implementación de las estrategias preventivas del síndrome post-UCI: estudio observacional multicéntrico en España. *Enferm Intensiva*. 2019;30:59–71, <http://dx.doi.org/10.1016/j.enfi.2018.04.004>.
- Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. *Crit Care Med*. 2009;37(10 Suppl):S299–308.
- Cid-Ruzafa J, Damián-Moreno J. Valoración de la discapacidad física: el índice de Barthel. *Rev. Esp. Salud Pública [Internet]*. 1997;71:127–37.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373–83.
- Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med*. 2002;166:1338–44. PMID: 12421743.
- Jenkinson C, Layte R. Development and testing of the UK SF-12 (Short form health survey). *J Health Serv Res Policy*. 1997;2:14–8.
- Vanpee G, Hermans G, Segers J, Gosselink R. Assessment of limb muscle strength in critically ill patients: a systematic review. *Crit Care Med*. 2014;42:701–11, <http://dx.doi.org/10.1097/CCM.000000000000030>.
- Argimon J, Jiménez J. Validación de cuestionarios. Métodos de investigación clínica y epidemiológica. 4th ed. Barcelona: Elsevier; 2013.

27. Nunnally JC, Bernstein IH. *Psychometric theory*. New York: McGraw-Hill Inc; 1994.
28. Fleiss JL. *The design and analysis of clinical experiments*. New York: Wiley; 1986.
29. Altman DG. *Practical statistics for medical research*. New York: Chapman and Hall; 1991.
30. Cohen J. *Statistical power analysis for the behavioural sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
31. Schunemann HJ, Guyatt GH. Commentary—goodbye M(C)ID! Hello MID, where do you come from? *Health Serv Res*. 2005;40:593–7.
32. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertain the minimal clinically important difference. *Controlled Clin Trials*. 1989;10:407–15.
33. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc*. 2006;54:743–9.
34. Luján-Tangarife JA, Cardona-Arias JA. Construcción y validación de escalas de medición en salud: revisión de propiedades psicométricas. *Arch Med*. 2015;11:1–10.
35. Garzon-Serrano J, Ryan C, Waak K, Hirschberg R, Tully S, Bittner EA, et al. Early mobilization in critically ill patients: Patients' mobilization level depends on health care provider's profession. *PMR*. 2011;3:307–13, <http://dx.doi.org/10.1016/j.pmrj.2010.12.022>. PMID: 21497316.
36. McWilliams D, Weblin J, Atkins G, Bion J, Williams J, Elliott C, et al. Enhancing rehabilitation of mechanically ventilated patients in the intensive care unit: a quality improvement project. *J Crit Care*. 2015;30:13–8, <http://dx.doi.org/10.1016/j.jcrc.2014.09.018>. PMID: 25316527.
37. Rebel A, Marzano V, Green M, Johnston K, Wang J, Neeman T, et al. Mobilisation is feasible in intensive care patients receiving vasoactive therapy: An observational study. *Aust Crit Care*. 2019;32:139–46, <http://dx.doi.org/10.1016/j.aucc.2018.03.004>.
38. Tipping CJ, Bailey MJ, Bellomo R, Berney S, Buhr H, Denehy L, et al. The ICU Mobility Scale Has Construct and Predictive Validity and Is Responsive. A Multicenter Observational Study. *Ann Am Thorac Soc*. 2016;13:887–93, <http://dx.doi.org/10.1513/AnnalsATS.201510-717OC>.
39. Wilches Luna EC, Hernández NL, Siriani de Oliveira A, Kenji Nawa R, Perme C, Gastaldi AC. Perme ICU Mobility Score (Perme Score) and the ICU Mobility Scale (IMS): translation and cultural adaptation for the Spanish language. *Colomb Med (Cali)*. 2018;49:265–72, <http://dx.doi.org/10.25100/cm.v49i3.4042>.
40. Kawaguchi YM, Nawa RK, Figueiredo TB, Martins L, Pires-Neto RC. Perme Intensive Care Unit Mobility Score and ICU Mobility Scale: translation into Portuguese and cross-cultural adaptation for use in Brazil. *J Bras Pneumol*. 2016;42:429–34, <http://dx.doi.org/10.1590/S1806-37562015000000301>.
41. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *J Clin Epidemiol*. 2008;61:102–9, <http://dx.doi.org/10.1016/j.jclinepi.2007.03.012>.